COMMUNIQUÉS West-GlobeNewswire

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock
27/10/2025
SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein [...]
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study
27/10/2025
- All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, [...]
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
27/10/2025
Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate [...]
World's First Multi-Omics LLM, Promising to Decode the Language of Human Biology Showcasing in Global Health Exhibition, Riyadh
27/10/2025
PanOmiQ’s foundational model trained on multi-Omics data breakthrough FPGA-powered deployment addresses data sovereignty challenge, ultrafast AI-driven multi-omics analysis on premises, redefining speed and accuracy in [...]
Citryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025
27/10/2025
CITRYLL PRESENTS POSITIVE DATA FROM PHASE I STUDY OF CIT-013 IN RHEUMATOID ARTHRITIS AT ACR CONVERGENCE 2025 Phase I trial data in rheumatoid arthritis patients demonstrates favorable safety, encouraging clinical [...]
Vivani Medical, Inc. Announces Pricing of Common Stock Offering
27/10/2025
ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease
27/10/2025
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) [...]
Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares
27/10/2025
MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors [...]
New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus
26/10/2025
Research on TissueCypher by Horvath et al. honored with a Presidential Poster Award from the ACG Abstract Selection Committee, a distinction awarded to only 5-7% of abstracts for research deemed high quality, novel or [...]
New Global Coalition Launches to Address the Hidden Threat of RSV in Adults
26/10/2025
VIENNA, Austria, Oct. 26, 2025 (GLOBE NEWSWIRE) -- A new global coalition, the RSV Alliance, has been launched to raise awareness about the risks of respiratory syncytial virus (RSV) infections, with a focus on aging [...]
MapLight Therapeutics Announces Pricing of Initial Public Offering
26/10/2025
SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous [...]
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
26/10/2025
Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the Novartis xRNA strategy by [...]
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
26/10/2025
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning [...]
mediCAD® 8 Revolutionizes Orthopedic and Trauma Planning with Intelligent AI Integration
26/10/2025
LANDSHUT, Germany, Oct. 26, 2025 (GLOBE NEWSWIRE) -- The latest release of mediCAD® 8 by mediCAD Hectec GmbH marks a new era in intelligent orthopedic and trauma planning. Combining artificial intelligence, automation, [...]
Polpharma Group annonce un changement de direction – Sebastian Szymanek nommé nouveau président
26/10/2025
AMSTERDAM, 26 oct. 2025 (GLOBE NEWSWIRE) -- Polpharma Group, l’un des plus grands groupes pharmaceutiques opérant en Europe centrale, orientale et en Asie centrale, annonce une transition planifiée de sa direction. À [...]
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
25/10/2025
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage [...]
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions
25/10/2025
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (e mapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in [...]
Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
25/10/2025
First-in-class dual payload peptide drug conjugate delivers two complementary therapies from a single molecule with potential to overcome resistance and maximize tumor control LONDON and PHILADELPHIA, Oct. 25, 2025 ( [...]
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
25/10/2025
Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically [...]

Pages